Sania Therapeutics

Targeted gene therapy for dysfunctional neural circuits

Sania has developed a gene-therapy platform to selectively target dysfunctional neural circuits in a more selective and safer manner than previously possible. The company has demonstrated in-vivo proof of concept and is preparing for IND-enabling studies.


How they’re delivering breakthroughs

  • Precision delivery of gene therapy only to affected neural circuits
  • Advantageous therapeutic window lays the foundation for neural gene therapies to become standard of care
  • Several pipeline programmes are underway

How they’re making a difference

  • Severe spasticity as a lead indication, which has no effective treatment and affects over 2M people US/EU alone
  • Wide applicability across conditions relying on neural control such as hypertension or neuropathic pain

The people behind the innovation

Andrew Murray, PhD
CEO & Co-Founder
Rob Brownstone, MD, PhD, FMedSci

Learn more about Sania Therapeutics

By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.